Medicine recalls
|
| |
| The United States: JaDera and Xiyouji Qingzhi Dietary Supplements by Dolphin Intertrade Corp.: Recall - Undeclared Drug Ingredient Sibutramine |
| |
Dolphin Intertrade Corp. is voluntary recalling “JaDera” and “Xiyouji Qingzhi” Weight Loss Supplement. These product have been found to contain undeclared Sibutramine, Sibutramine was a previously approved controlled substance for the treatment of obesity that was removed from the U.S. market in October 2010 for safety reasons, making this product an unapproved new drug. Products containing Sibutramine pose a threat to consumers because Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias or stroke. These products may also interact in life threatening ways with other medications a consumer may be taking. The company has not received any reports of adverse events related to this recall. The recall was initiated after discovering that Sibutramine was included as an ingredient by the manufacture Consumers and distributors that have product which is being recalled should stop using the products and return the product to Dolphin Intertrade Corp. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product
Please refer to the following website in FDA for details:
http://www.fda.gov/Safety/MedWatch/../ucm359072.htm
In Hong Kong, the above products are not registered pharmaceutical products. Related news has been released by FDA, TGA and Health Canada, and was posted on Drug Office website on 11 June 2013, 9 March and 25 May 2012 respectively.
Ends/ Saturday, June 29, 2013
Issued at HKT 17:00
|
| |
|
